Elicera Therapeutics AB (OSTO:ELIC) Forward Dividend Yield %: 0.00% (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ELIC Elicera Therapeutics AB OSTO:ELIC
25 GF Score
Price kr2.62
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB Forward Dividend Yield %?

Elicera Therapeutics AB OSTO:ELIC -1.50% 25 Forward Dividend Yield % is 0.00% as of Jul. 16, 2026. GuruFocus rates OSTO:ELIC with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 149 Biotechnology companies, Elicera Therapeutics AB ranks worse than 671140.27% on this metric.

As of today (2026-07-16), the Forward Annual Dividend Yield of Elicera Therapeutics AB is 0.00%.

As of today (2026-07-16), the Trailing Annual Dividend Yield of Elicera Therapeutics AB is 0.00%.

OSTO:ELIC's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.31
* Ranked among companies with meaningful Forward Dividend Yield % only.

Elicera Therapeutics AB's Dividends per Share for the three months ended in Mar. 2026 was kr0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Elicera Therapeutics AB  (OSTO:ELIC) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Elicera Therapeutics AB Forward Dividend Yield % Related Terms

OSTO:ELIC vs VRTX, REGN, ALNY: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Elicera Therapeutics AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicera Therapeutics AB Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's Forward Dividend Yield % falls into.


OSTO:ELIC
25GF Score
Elicera Therapeutics AB OSTO:ELIC
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Elicera Therapeutics AB (OSTO:ELIC) has a Forward Dividend Yield % of 0.00% as of Jul. 16, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Elicera Therapeutics AB and its competitors. According to the industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 149 companies in the Biotechnology industry.
Is Elicera Therapeutics AB's Forward Dividend Yield % too high?
Elicera Therapeutics AB's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Elicera Therapeutics AB ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Elicera Therapeutics AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's Forward Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Elicera Therapeutics AB ranks #999999 out of 149 companies for Forward Dividend Yield %. This places Elicera Therapeutics AB in the lower half of its industry. The industry median Forward Dividend Yield % is 1.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.31, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Elicera Therapeutics AB and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elicera Therapeutics AB's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (OSTO:ELIC) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Elicera Therapeutics AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Elicera Therapeutics AB (OSTO:ELIC), the current Forward Dividend Yield % is 0.00% as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicera Therapeutics AB Business Description

Other Exchanges 8E8:Germany
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
25GF Score

Get the complete analysis for OSTO:ELIC

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.62
Price